Tweet by Alberto J Espay on infographic. Donanemab in AD Posted byJoseph Thornton MDJuly 18, 2023Posted inBlog Alberto J Espay @AlbertoEspay Donanemab in early symptomatic Alzheimer’s disease – Infographic of the phase 3 trial data published by JAMA earlier today. Highlights: • No improvement • ~3-point less worsening in iADRS (below MCID) • 3.4% slower decline (not 35%!) @alzforum @alzassociation pic.twitter.com/5vbEt6NEOv 7/17/23, 3:59 PM Joseph Thornton Share this: Share on X (Opens in new window) X Share on Facebook (Opens in new window) Facebook Like Loading... Related Published by Joseph Thornton MD Teacher, Clinical Supervisor, [AIdvisor] Retired Clinical Associate Professor, Psychiatry, University of Florida Affiliation is for identification only. All content and opinions are my own. View more posts
Gator Psychiatry 